Medice Arzneimittel Pütter GmbH & Co KG   Report issue

For profit Phase 2 Phase 3 Phase 4
Founded: Iserlohn Germany (1949)
Status: No NME R&D (1949)

Organization Overview

First Clinical Trial
2004
NCT00619840
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Alternative names

MEDICE Arzneimittel Puetter GmbH&Co.KG | Medice Arzneimittel Pütter GmbH & CoKG | Medice Arzneimittel Pütter GmbH & Co KG

Active Ingredients

Drugs in Phase 4 Trials (2)

benzalkonium (1 trial)

benzocaine (1 trial)

Drugs in Phase 3 Trials (1)

methylphenidate (ritalin) (3 trials)

Drugs in Phase 2 Trials (2)

nicotinamide (1 trial)

sodium bicarbonate (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Attention Deficit Disorder with Hyperactivity (Phase 3)

Calcinosis (Phase 2)

Fatigue (Phase 3)

Hyperkinesis (Phase 3)

Hyperphosphatemia (Phase 2)

Kidney Diseases (Phase 2)

Pharyngitis (Phase 4)

Renal Insufficiency, Chronic (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 6
  • # of Trial APIs: 5